No Data
No Data
Zevra Therapeutics Board And Management Urge Stockholders to Vote "FOR" Zevra's Director Nominees on WHITE Proxy Card
Zevra Details Strong Growth, Director Re-Election and Strategic Vision for Rare Disease Treatments in Stockholder Letter Ahead of 2025 Annual Meeting
Express News | Zevra Therapeutics Inc - Board Recommends Voting 'for' Wendy L. Dixon and Tamara a. Favorito
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
Zevra Therapeutics Publishes Study on Arimoclomol's Mechanism of Action in Niemann-Pick Type C Disease
Express News | Zevra Announces Publication of Miplyffa® Mechanism of Action Manuscript in Molecular Genetics and Metabolism